It's easy to determine why BioNTech stock is dropping. Results from a clinical trial conducted in Israel found that a fourth dose of the COVID vaccine developed by BioNTech and its big partner, Pfizer (NYSE: PFE), didn't prevent infection by the coronavirus omicron variant.
Is biontech stock likely to continue trending lower?
May 04, 2021 · So why did BioNTech's shares slide? The most likely reason is that the mood of the overall stock market is weighing on this biotech stock. Some investors could also be taking profits off the table...
What is the fundamental picture like for biontech?
Aug 10, 2021 · Shares of BioNTech ( BNTX-5.46%) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival ... Why BioNTech Stock Dropped 12.4% in ...
Is biontech’s research pipeline more valuable than Moderna?
Nov 04, 2021 · From an objective point of view, there's no reason BioNTech's shares should have dropped because of Moderna's problems. BioNTech's partner, Pfizer ( PFE -2.00% ), increased the 2021 sales guidance...
Is bntx stock poised to rise or fall?
Jan 18, 2022 · It's easy to determine why BioNTech stock is dropping. Results from a clinical trial conducted in Israel found that a fourth dose of the COVID vaccine developed by …
Is BioNTech a good investment?
If you're an investor who typically invests in biotech stocks and is comfortable with the risks that they entail, I'd say that buying BioNTech today isn't a terrible decision. In the long run, its research and development activity should pay off, and it's in no great hurry for its pipeline projects to bear fruit.Mar 12, 2022
Why is Pfizer stock going down today?
Pfizer CEO Albert Bourla talks. Pfizer shares dropped sharply after the company's 2022 sales guidance appeared to fall short of expectations. The guidance that Pfizer (ticker: PFE) presented, however, doesn't take into account future sales of Pfizer's Covid-19 vaccine and antiviral, but only sales already made.Feb 9, 2022
Is BNTX stock a buy?
The Biontech Se Sponsored Adr stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Why is mRNA stock dropping?
Moderna Inc.'s shares have dropped 50% this year as investors pulled back from Covid-19 healthcare stocks and staged a broader rotation out of growth names. The biotech firm fell 7.3% on Monday amid a broader market selloff and has erased $52 billion in value this year.Mar 7, 2022
Will Pfizer stock go up in 2022?
17, 2022. Depending on which analyst you believe, you should expect either a loss of 42% or gains of up to 246%, with a consensus expectation of an 86% gain. Year-to-date, the stock is already down over 42%, but investors who bought in before the pandemic are still sitting pretty.Feb 21, 2022
Why was Pfizer removed from NYSE?
“The 0.250% Notes due 2022 were euro denominated notes that were paid in full on March 7, 2022 in accordance with their terms and maturity date,” the Pfizer spokesperson wrote, referring to Pfizer's debt security. “As a result, the 0.250% Notes due 2022 are no longer outstanding and thus are delisted from the NYSE.”Mar 19, 2022
How high will BioNTech stock go?
On average, Wall Street analysts predict that BIONTECH SE's share price could reach $277.13 by Apr 12, 2023. The average BIONTECH SE stock price prediction forecasts a potential upside of 58.1% from the current BNTX share price of $175.29.
Why is BNTX going up?
The gain came after multiple news organizations reported that BioNTech and its big partner, Pfizer ( PFE -0.86% ), are expected to soon file for U.S. Emergency Use Authorization (EUA) of their COVID-19 vaccine in children ages 6 months to 5 years.Feb 1, 2022
What is the target price for BNTX?
BioNTech SE (NASDAQ:BNTX) The 14 analysts offering 12-month price forecasts for BioNTech SE have a median target of 248.58, with a high estimate of 356.79 and a low estimate of 163.13. The median estimate represents a +46.91% increase from the last price of 169.21.
How much did Moderna make from Covid vaccine?
The US government has provided Moderna with nearly $10 billion in taxpayer money for both research and development and for the purchase of 500 million doses of this mRNA COVID-19 vaccine. This includes almost the entire cost of clinical development.Nov 4, 2021
Why is Moderna tanking?
Moderna Stock Is Falling for a Fifth Straight Trading Session. Shares of Moderna were dropping for the fifth consecutive day on Monday, following a report that the vaccine maker was fighting a shareholder proposal demanding the company open up its Covid-19 vaccine technology and pricing to low-income countries.Dec 27, 2021
Why did Novavax drop today?
Why Novavax Stock Dropped 23.6% This Week The company is still waiting for the FDA to give Emergency Use Authorization for its COVID-19 vaccine.
Researchers might have found some difference between mRNA vaccine makers
Jason covers stocks for the Fool. He leans on his consulting background and executive experience in the human capital management and healthcare industries to offer analysis of individual companies.
What happened
Shares of BioNTech ( NASDAQ:BNTX) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna 's ( NASDAQ:MRNA) vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.
So what
With so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.
Now what
It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary.
Moderna's disappointing Q3 report appears to be dragging BioNTech's shares down with it.
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of BioNTech ( NASDAQ:BNTX) were 9.1% lower as of 11:51 a.m. EDT on Thursday. The German biotech didn't report any news, so why did its stock slide? You can probably blame Moderna ( NASDAQ:MRNA).
So what
From an objective point of view, there's no reason BioNTech's shares should have dropped because of Moderna's problems. BioNTech's partner, Pfizer ( NYSE:PFE), increased the 2021 sales guidance for their COVID vaccine, Comirnaty, in its third-quarter update earlier this week.
Now what
Instead of focusing on Moderna's third-quarter results, investors are better off waiting to hear what BioNTech has to say in its own third-quarter update, scheduled for Nov. 9.
What happened
Shares of several top COVID-19 vaccine makers were sinking as of 10:22 a.m. ET on Tuesday. BioNTech (NASDAQ: BNTX) was being hit the hardest, with the stock down 9.8%. Shares of Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) had fallen 7.4% and 8.2%, respectively.
Now what
BioNTech and Pfizer expect to have their omicron-specific vaccine ready by March 2022. Moderna hopes to share data with regulators from its testing of an vaccine targeting omicron around the same time.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
